SEOM-GEICO clinical guidelines on endometrial cancer (2021)

被引：0
作者：
María Pilar Barretina-Ginesta
María Quindós
Jesús Damián Alarcón
Carmen Esteban
Lydia Gaba
César Gómez
José Alejandro Pérez Fidalgo
Ignacio Romero
Ana Santaballa
María Jesús Rubio-Pérez
机构：
[1] Institut Català d’Oncologia (ICO),Medical Oncology Department
[2] Department of Medical Sciences,Medical Oncology Department
[3] Girona Biomedical Research Institute (IDIBGI). Department of Medical Sciences,Medical Oncology Department
[4] Medical School University of Girona (UdG),Medical Oncology Department
[5] Complexo Hospitalario Universitario de A Coruña. Biomedical Research Institute (INIBIC),Medical Oncology Department, Hospital Clínic of Barcelona, Therapeutics in Solid Tumors
[6] Hospital Universitari Son Espases,Department of Medical Oncology, Infanta Sofía and Henares Hospitals Foundation for Biomedical Research and Innovation (FIIB HUIS HHEN)
[7] Fundació Institut d’Investigació Sanitària Illes Balears (IdISBa),Medical Oncology Department
[8] Complejo Hospitalario de Toledo,Department of Medical Oncology
[9] Translational Genomic and Targeted,Medical Oncology Department
[10] Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS),Medical Oncology Department
[11] Infanta Sofía University Hospital,undefined
[12] Hospital Clínico Universitario of Valencia. Biomedical Research Institute INCLIVA. CIBERONC,undefined
[13] Fundación Instituto Valenciano de Oncología (IVO),undefined
[14] Hospital Universitari i Politècnic La Fe,undefined
[15] Hospital Universitario Reina Sofía. University of Córdoba,undefined
来源：
Clinical and Translational Oncology | 2022年 / 24卷
关键词：
Endometrial cancer; Guideline; Diagnosis; Treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Endometrial cancer (EC) is the second most common gynecological malignancy worldwide, the first in developed countries [Sung et al. in CA Cancer J Clin 71:209–249, 2021]. Although a majority is diagnosed at an early stage with a low risk of relapse, an important proportion of patients will relapse. Better knowledge of molecular abnormalities is crucial to identify high-risk groups in early stages as well as for recurrent or metastatic disease for whom adjuvant treatment must be personalized. The objective of this guide is to summarize the current evidence for the diagnosis, treatment, and follow-up of EC, and to provide evidence-based recommendations for clinical practice.
引用
收藏
页码：625 / 634
页数：9
相关论文
共 211 条
[11]  
Bachmann LM(2019)Integrated genomic characterization of endometrial carcinoma Nat Rev Cancer 19 510-365
[12]  
Epstein E(2013)Molecular classification and emerging targeted therapy in endometrial cancer Nature 497 67-218
[13]  
Clark TJ(2020)Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis Int J Gynecol Pathol 39 26-41
[14]  
Lin MY(2021)Revised FIGO staging for endometrial cancer J Pathol. 253 355-39
[15]  
Dobrotwir A(2011)ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up Clin Obstet Gynecol 54 215-104
[16]  
McNally O(2016)ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma Ann Oncol 27 16-1716
[17]  
Abu-Rustum NR(2021)Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium Int J Gynecol Cancer 31 12-36
[18]  
Narayan K(2009)Laparoscopy versus laparotomy for the management of early stage endometrial cancer Int J Gynaecol Obstet 105 103-392
[19]  
Bercow AS(2012)Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial Cochrane Database Syst Rev 12 CD006655-18
[20]  
Eisenhauer EL(2008)Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study J Natl Cancer Inst 100 1707-393
12345678910